Health Insurance

HHS is tasked with monitoring denials both by ACA plans and those offered through employers and insurers. As ’ denials become more common, they sometimes defy not just medical standards but sheer logic. Why hasn’t the agency fulfilled its assignment?

Georgia is among 35-plus states that have used an under-the-radar federal funding mechanism to boost payments for hospitals and other providers under Medicaid. But oversight makes it hard to tell if the “directed payments” program is meeting its goals.

Under KidCare, families who do not qualify for Medicaid can pay $15 or $20 a month in premiums to insure children.

A federal judge’s recent ruling on the Affordable Care Act is by no means the final word. Even parsing its impact is complicated. Here are key issues to watch as the case works its way through the legal system.

Hundreds of thousands of Floridians stand to lose Medicaid after a provision that allowed for continuous enrollment in the program comes to an end Saturday. The program began at the start of the pandemic.

Now that pandemic protections are expiring, millions of Floridians will have to reapply for Medicaid and some could lose coverage. But families don't have to go through the process alone.

U.S. Rep. Kathy Castor wants Gov. Ron DeSantis to make use of Florida’s Affordable Care Act marketplace to help families remain covered.

Shopping for insurance that covers regular doctors and prescriptions can be daunting. But experts see several steps to make it easier.

Designed to prevent doctors from deploying expensive, ineffectual procedures, preauthorization has morphed into a monster that denies or delays care, burdens physicians with paperwork and perpetuates racial disparities.

Close to 40% of surveyed Americans, a record high, put off medical care last year because of finances. Americans are delaying or skipping doctor's visits, dental and vision care, and medications.

Patients who depend upon special drugs to treat rare diseases are caught in the crossfire as drugmakers and the FDA battle over regulations that reward companies for developing treatments for relatively small pools of patients.

Plaintiffs’ attorneys and many Democratic lawmakers argue that trying to limit lawsuits and legal fees will unfairly affect injured people.